Nausea and vomiting are common complications in patients undergoing caesarean delivery under regional anaesthesia. When experienced after surgery, they may delay recovery, reduce patient satisfaction and affect the bonding between mother and baby. Various pharmacological and non-pharmacological approaches for prophylaxis and treatment of postoperative nausea and vomiting (PONV) have been employed with different degree of efficacy. In this pilot randomised controlled trial, we aimed to determine the possible preventative effects of chewing gum on the rate of PONV in expectant mothers undergoing neuraxial anaesthesia for elective lower segment caesarean section. All participants underwent spinal anaesthesia with administration of 10-11.5 mg of intrathecal heavy Bupivicaine 0.5% according to anaesthetists' preference, Morphine 100 μg and Fentanyl 25 μg. Postoperative analgesia regimen was also standardised. Two hundred ninety-six patients were randomised to an intervention arm to receive chewing gum in addition to standard therapy and to a non-intervention arm to receive standard therapy. After exclusions, 258 patients were followed up 24 h postoperatively. Standard therapy is defined as Ondansetron 4 mg IV intra-operatively. The primary outcomes were the incidences of nausea and vomiting in the first 24 h postoperatively. Secondary outcomes were the number of episodes of nausea or vomiting in the recovery room and on the ward 24 h postoperatively, use of anti-emetics postoperatively, severity of nausea and patient satisfaction with the intervention. Our study revealed no significant differences in rates of postoperative nausea and vomiting between the intervention and standard therapy groups (41.4% v 36.9% p = 0.461). There were no significant differences in secondary outcomes between groups. Chewing gum does not reduce the incidence of PONV after elective LSCS under spinal anaesthesia. Our trial was registered with clinicaltrials.org (NCT04191694).
BackgroundNausea and Vomiting are common complications in patients undergoing Caesarean delivery under regional anaesthesia. When experienced after surgery, they may not only delay recovery, reduce patient satisfaction and affect the bonding between mother and baby but also may increase the risk of aspiration, which is a recognised cause of maternal death. Various pharmacological and nonpharmacological approaches for prophylaxis and treatment of post-operative nausea and vomiting (PONV) have been employed with different degree of e cacy.
AimsIn this pilot randomised controlled trial, we aimed to determine the possible preventative effects of chewing gum on the rate of PONV in expectant mothers undergoing neuraxial anaesthesia for elective lower segment caesarean section. Methods 296 patients were randomised to an intervention arm to receive chewing gum in addition to standard therapy and to a non-intervention arm to receive standard therapy. After exclusions 258 patients were followed up 24 hours post-operatively. Standard therapy is de ned as Ondansetron 4mg IV intraoperatively. The primary outcomes were the incidences of nausea and vomiting in the rst 24 hours postoperatively. Secondary outcomes were the number of episodes of nausea or vomiting in the recovery room and on the ward 24 hours post-operatively, use of anti-emetics post-operatively, severity of nausea and patient satisfaction with the intervention.
ResultsOur study revealed no signi cant differences in rates of post-operative nausea and vomiting between the intervention and standard therapy groups (41.4% v 36.9% p = 0.461). There were no signi cant differences in secondary outcomes between groups.
ConclusionChewing gum does not reduce the incidence of PONV after elective LSCS under spinal anaesthesia
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.